ДЕЯКІ АСПЕКТИ МЕТАБОЛІЧНОЇ ТЕРАПІЇ ЗАХВОРЮВАНЬ СЕРЦЕВО-СУДИННОЇ СИСТЕМИ (огляд літератури)
DOI:
https://doi.org/10.24061/1727-4338.XV.2.56.2016.44Ключові слова:
ішемічна хвороба серця, аденозинтрифосфорна кислота, метаболічна терапія, триметазидин, мельдоній, ритмокорАнотація
Наводяться дані літератури про синтез аденозинтрифосфорної кислоти (АТФ) в міокарді в нормі та при коронарному атеросклерозі. Описується механізм дії міокардіальних цитопротекторів триметазидину, мельдонію та ритмокору при кардіальній патології.Посилання
Amosova EN. Metabolicheskaja terapija povrezhdenij miokarda, obuslovlennogo ishemiej: novyj podhod k lecheniju ishemicheskoj bolezni serdca i serdechnoj nedostatochnosti [Metabolic therapy of myocardial damage caused by ischemia: a new approach to the treatment of coronary heart disease and heart failure]. Ukrainskyi kardiolohichnyi zhurnal. 2000;4:86-92. (in Russian).
Bobrov VO, Kulishov SK. Adaptatsiini ishemichni ta reperfuziini syndromy u khvorykh ishemichnoiu khvoroboiu sertsia: mekhanizmy, diahnostyka, obgruntuvannia terapii [Adaptive ischemic and reperfusion syndromes in patients with coronary heart disease: mechanisms, diagnostics, therapeutic substantiation]. Poltava: Dyvosvit; 2004. 240 с. (in Ukrainian).
Kuznecov MR, Virganskij AO, Kosyh IV, Jumin SM, Kunicyn NV, Golosnickij PJu, i dr. Vozmozhnosti metabolicheskoj terapii pri aterosklerozeju [The possibilities of metabolic therapy for atherosclerosis]. Nevrologicheskij zhurnal. 2014;4:56-60. (in Russian).
Netjazhenko VZ, Mal'chevskaja TI, Mishanich GI, Zalevskaja TD, Mashkevich AG. Vybor metabolicheskoj terapii pri lechenii bol'nyh s ishemicheskoj bolezn'ju serdca [The choice of metabolic therapy in the treatment of patients with ischemic heart disease]. Novosti mediciny i farmacii. 2010;7:8. (in Russian).
Holovach IIu, Avramenko OM. Vykorystannia korektoriv metabolizmu na osnovi mel'doniiu dyhidratu: suchasnyi pidkhid u kombinovanii terapii ishemichnykh zakhvoriuvan' sertsia [The use of correctors of metabolism on the basis of meltedonium dihydrate: a modern approach in the combined therapy of ischemic heart disease]. Liky Ukrainy. 2011;8:68-72. (in Ukrainian).
Zaremba YeKh, Karpliak VM. Tsytoprotektorna terapiia sertsevo-sudynnykh zakhvoriuvan' [Cytoprotective therapy of cardiovascular diseases]. L'vivs'kyi medychnyi chasopys. 2011;17(1):106-11. (in Ukrainian).
Lishnevskaja VJu, Papuga MS, El'nikova VA. Metabolicheskaja terapija v kardiologii: sovremennye podhody k vyboru preparatov [Metabolic therapy in cardiology: modern approaches to the choice of drugs]. Praktychna anhiolohiia. 2007;4:61-4. (in Russian).
Lishnevskaja VJu. Metabolicheskaja terapija pri IBS - iz proshlogo v budushhee [Metabolic therapy with ischemic heart disease - from the past to the future]. Consilium medicum Ukraina. 2008;1:34-9. (in Russian).
Olesova VM, Markatjuk OJu, Jurova JuJu, Obrezan AG. Metabolizm miokarda i preparaty metabolicheskogo dejstvija [Metabolism of the myocardium and drugs of metabolic action]. Kardiologija. 2013;1: 66-71. (in Russian).
Korkushko OV, ShatiloVB, Jaroshenko JuT, Ishhuk VA, Kozlovskij VA, Kutnjak VP. Metabolicheskaja terapija kak perspektivnoe napravlenie lechenija pacientov s ishemicheskoj bolezn'ju serdca [Metabolic therapy as a promising treatment for patients with ischemic heart disease]. Krovoobih ta hemostaz. 2008;2:5-15. (in Russian).
Bobrov VA, Bobrova EV, Medvedenko ON, Davydova IV, Makarevskij AI. Metabolicheskaja terapija: celesoobrazno li ee primenenie pri lechenii serdechno-sosudistyh zabolevanij [Metabolic therapy: is it advisable to use it in the treatment of cardiovascular diseases]? Mystetstvo likuvannia. 2011;3:72-6. (in Russian).
Vizir VA, Voloshina IN, VoloshinNA, Mazur IA, Belenichev IF. Metabolicheskie kardioprotektory: farmakologicheskie svojstva i primenenie v klinicheskoj praktike [Metabolic cardioprotectors: pharmacological properties and application in clinical practice]: metod. rek. Zaporozh'e: GMU;2006. 34 с. (in Russian).
Mihin VP, Hlebodarov FE. Perspektivy primenenija mildronata u bol'nyh s serdechno-sosudistoj patologiej [Prospects of using mildronate in patients with cardiovascular pathology]. Rossijskij kardiologicheskij zhurnal. 2010;4:158-68. (in Russian).
Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy na zasadakh dokazovoi medytsyny [On approval and implementation of medical-technological documents on standardization of medical care on the basis of evidence-based medicine]. Nakaz MOZ Ukrainy № 816 vid 23.11.2011. [Internet]. Kyiv; 2011 [tsytovano 2016 Jun 14]. Dostupno: http://search.ligazakon.ua/l_doc2.nsf/link1/MUS3725.html. (in Ukrainian).
Lutaj MI, Lysenko AF, Tovstuha VV, Moiseenko OI. Ocenka antianginal'noj jeffektivnosti mel'donija (Trizipina) u pacientov so stabil'noj ishemicheskoj bolezn'ju serdca i stenokardiej naprjazhenija [Evaluation of the antianginal efficacy of meldonium (Trisipin) in patients with stable ischemic heart disease and angina pectoris]. Ukrains'kyi medychnyi chasopys. http://m.umj.com.ua/article/magazine/102">2014:4:50-3. (in Russian).
Bilets'kyi SV, Koval'chuk LIu, Petrynych OA, Kazantseva TV. Pokaznyky prooksydantno-antyoksydantnoho homeostazu ta vmist monooksydu nitrohenu u krovi khvorykh na hipertonichnu khvorobu v poiednanni z ishemichnoiu khvoroboiu sertsia [Indicators of prooxidant antioxidant homeostasis and the content of nitrogen monoxide in the blood of patients with hypertension in combination with ischemic heart disease]. Bukovyns'kyi medychnyi visnyk. 2013;17(3, Ч. 2):125-28. (in UkrainianМистецтво лікування. 2011;1:80-5. (in Russian).
Chekman IS, Datsiuk NO, Luk’ianova OM, Zahorodnii MI. Rol' perekysnoho okyslennia lipidiv u patohenezi arterial'noi hipertenzii [The Role of Peroxide Oxidation of Lipids in the Pathogenesis of Arterial Hypertension]. Liky Ukrainy. 2008;6:76-81. (in Ukrainian).
Tarasova KV, Frantsuzova SB. Vikovi osoblyvosti enerhetychnoho zabezpechennia miokarda: vplyv aktyvatoriv K+ATF- kanaliv. [Age features of energy supply of the myocardium: the effect of activators of K + ATP channels]. Problemy starenija i dolgoletija. 2013;22(3):234-48. (in Ukrainian).
Shahnovich R.M. Optimizacija jenergeticheskogo metabolizma u bol'nyh ishemicheskoj bolezn'ju serdca [Optimization of energy metabolism in patients with ischemic heart disease]. Russkij medicinskij zhurnal. 2001;15:622-628. (in Russian).
Korkushko OV, ShatiloVB, Asanov JeO, Tarasenko OB, Dmitrieva II. Jeffektivnost' i bezopasnost' Ritmokora u pozhilyh bol'nyh s ishemicheskoj bolezn'ju serdca i jekstrasistolicheskoj aritmiej [Efficacy and safety of Rtmocor in elderly patients with ischemic heart disease and extrasystolic arrhythmia]. Krovoobih ta hemostaz. 2005;3-4:171-76. (in Russian).
Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM. Guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 1999 Jun;33(7):2092-197.
Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of Trimetezidine with nifedipine in effort angina: double-blind, crossover study. Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 4:853-9.
Grynberg A, Demaison L.Fatty acid oxidation in the. https://www.ncbi.nlm.nih.gov/pubmed/8891866">J Cardiovasc Pharmacol. 1996;28 Suppl 1:S11-7.
Cargnoni A, Pasini E, Ceconi C. Insight into cytoprotection with metabolic agents. Eur. Heart J. (Suppl.). 1999;1:40-8.
Makolkin V, Osadchiy K. Trimetazidine modified release in the treatment of stable angina. TRIUMPH Study. https://www.ncbi.nlm.nih.gov/pubmed/17523736">Clin Drug Investig. 2004;24(12):731-8.
Stanley WC. Metabolic link between ischemia and cardiac dysfunction. Heart Metab. 2005;27:30-3.
MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2003 Aug 8;93(3):e26-32. DOI: 10.1161/01.RES.0000086943.72932.71.
Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000 Mar 17;86(5):580-8.
Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994 Mar;37(3):279-88.
Ussher JR, Lopaschuk GD. Clinical implications of energetic problems in cardiovascular disease. Heart Metab. 2006;32:9-17.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2018 S. V. Biletskyi, V. V. Boyko, O. A. Petrynych, T. V. Kazantseva
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Часопис користується «Типовим шаблоном положення про авторські права».
